45
Participants
Start Date
March 1, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
June 1, 2026
Benralizumab 30 mg/ml
Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks
RECRUITING
Pulmonary Clinic, Aristotle University of Thessaloniki, George Papanikolaou Hospital, Thessaloniki
Pulmonary Clinic, University of Ioannina
UNKNOWN
Pulmonary Clinic, Democritus University of Thrace
UNKNOWN
2nd Pulmonary Clinic, Kapodistrian University of Athens
UNKNOWN
University Hospital of Crete
OTHER
Pulmonary and Respiratory Failure Department, National and Kapodistrian University of Athens
UNKNOWN
University Hospital of Patras
OTHER
Aristotle University Of Thessaloniki
OTHER